# Inventiva S.A.: overview IVA · Nasdaq · CIK 1756594 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/iva.md) · [Financials](/companies/iva/financials.md) · [Filings](/companies/iva/filings.md) · [Insiders](/companies/iva/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2020 (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.4](/filings/0001104659-23-038571.md) | [4.2](/filings/0001104659-24-042817.md) | [12.2](/filings/0001104659-25-035122.md) | [17.5](/filings/0001104659-25-035122.md) | [9.2](/filings/0001104659-25-035122.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(7988.7%)](/filings/0001104659-23-038571.md) | [(1242.6%)](/filings/0001104659-24-042817.md) | [(468.9%)](/filings/0001104659-25-035122.md) | [(587.7%)](/filings/0001104659-25-035122.md) | [(1060.6%)](/filings/0001104659-25-035122.md) | | Net margin | % | not reported | [(1183.5%)](/filings/0001104659-22-032953.md) | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.99)](/filings/0001104659-23-038571.md) | [(1.27)](/filings/0001104659-24-042817.md) | [(1.31)](/filings/0001104659-25-035122.md) | [(2.43)](/filings/0001104659-25-035122.md) | [(3.08)](/filings/0001104659-25-035122.md) | | Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: ifrs-full:Revenue. - Gross margin (gross profit / revenue). XBRL Revenue: ifrs-full:Revenue. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue. - Net margin (net income / revenue). XBRL Revenue: ifrs-full:Revenue; Net income: ifrs-full:ProfitLoss. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/iva/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Caligan Partners LP](/funds/1727492.md) | 2026-06-30 | $30.9m | 8,163,191 | | Added +3,188,285 | | [SAMSARA BIOCAPITAL, LLC](/funds/1744967.md) | 2026-06-30 | $23.9m | 6,314,805 | | Added +1,120,000 | | [Paradigm Biocapital Advisors LP](/funds/1855655.md) | 2026-06-30 | $15.1m | 4,000,000 | | Unchanged | | [ANDERA PARTNERS](/funds/1757283.md) | 2026-06-30 | $13.7m | 3,633,181 | | Added +1,815,000 | | [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $13.6m | 3,606,656 | | Added +1,432,258 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $13.3m | 3,512,174 | | Added +524,561 | | [SymBiosis Capital Partners, LLC](/funds/2006045.md) | 2026-03-31 | $13.1m | 2,354,000 | | Not compared | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $10.2m | 2,686,393 | | New +2,686,393 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $10.2m | 2,686,393 | | New +2,686,393 | | [Trails Edge Capital Partners, LP](/funds/2077247.md) | 2026-06-30 | $10.0m | 2,657,997 | | Unchanged | ## Recent filings [All 228 filings](/companies/iva/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-06 | 17:01 ET | [6-K](/filings/0001171843-26-006471.md) | Report of a foreign private issuer, period 2026-10-06 | 0001171843-26-006471 | | 2026-09-28 | 07:07 ET | [6-K](/filings/0001104659-26-111143.md) | Report of a foreign private issuer, period 2026-06-30 | 0001104659-26-111143 | | 2026-09-03 | 06:00 ET | [6-K](/filings/0001171843-26-005860.md) | Report of a foreign private issuer, period 2026-09-02 | 0001171843-26-005860 | | 2026-09-01 | 18:16 ET | [6-K](/filings/0001171843-26-005810.md) | Report of a foreign private issuer, period 2026-08-31 | 0001171843-26-005810 | | 2026-07-29 | 16:22 ET | [6-K](/filings/0001171843-26-005018.md) | Report of a foreign private issuer, period 2026-07-29 | 0001171843-26-005018 | | 2026-07-09 | 16:40 ET | [6-K](/filings/0001171843-26-004554.md) | Report of a foreign private issuer, period 2026-07-09 | 0001171843-26-004554 | | 2026-07-06 | 06:00 ET | [6-K](/filings/0001171843-26-004459.md) | Report of a foreign private issuer, period 2026-07-02 | 0001171843-26-004459 | | 2026-06-12 | 16:45 ET | [6-K](/filings/0001104659-26-073545.md) | Report of a foreign private issuer, period 2026-06-12 | 0001104659-26-073545 | | 2026-06-12 | 06:22 ET | [6-K](/filings/0001104659-26-073144.md) | Report of a foreign private issuer, period 2026-06-12 | 0001104659-26-073144 | | 2026-06-09 | 16:20 ET | [6-K](/filings/0001171843-26-004003.md) | Report of a foreign private issuer, period 2026-06-09 | 0001171843-26-004003 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-040704.md), filed Apr 8, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1756594 - Tickers: IVA, IVEVF - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: I0 - Filer category: Accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 18:57 ET. No prices; not investment advice.